Investor Relations (IR) Questions: Anthera Pharmaceuticals ANTH
Click here to return to the biotech IRQ Index
Answers received: January 2013
Responses transcribed from a telephone conversation with Biana Nery and confirmed via email.
1) Now that the company has announced an offering, what are the plans with the proceeds?
The proceeds will primarily be applied to advance the company's pipeline in 2 different areas:
a) Phase 2 Bright SC - IgA Nephropathy Study Design. The first patient is expected to be enrolled in the 2nd quarter. (The company will at some point apply for Orphan status with the FDA.)
b) Phase 3 Lupus trial (the trial is broken up into two studies, Chablis SC1 and Chablis SC2). The first patient is expected to enroll in SC1 at the end of the 1stquarter / beginning of the 2nd quarter.
2) How much cash (not cash equivalents) does ANTH have?
The company last reported having $42.5 million in cash and equivalents as of September 2012.
3) What and approximately when is the next known catalyst?
There will be an 8 week interim analysis of the Bright SC phase 2 study published by year end. Timing of application for Orphan Drug status has not been disclosed.
Responses transcribed from a telephone conversation with Biana Nery and confirmed via email.
1) Now that the company has announced an offering, what are the plans with the proceeds?
The proceeds will primarily be applied to advance the company's pipeline in 2 different areas:
a) Phase 2 Bright SC - IgA Nephropathy Study Design. The first patient is expected to be enrolled in the 2nd quarter. (The company will at some point apply for Orphan status with the FDA.)
b) Phase 3 Lupus trial (the trial is broken up into two studies, Chablis SC1 and Chablis SC2). The first patient is expected to enroll in SC1 at the end of the 1stquarter / beginning of the 2nd quarter.
2) How much cash (not cash equivalents) does ANTH have?
The company last reported having $42.5 million in cash and equivalents as of September 2012.
3) What and approximately when is the next known catalyst?
There will be an 8 week interim analysis of the Bright SC phase 2 study published by year end. Timing of application for Orphan Drug status has not been disclosed.